### 502126903 11/13/2012

### PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

## **CONVEYING PARTY DATA**

Name	Execution Date
University of Maryland Biotechnology Institute	04/01/2010

# RECEIVING PARTY DATA

Name:	University of Maryland, Baltimore
Street Address:	620 W. Lexington Street, 4th floor
Internal Address:	Office of Research & Development
City:	Baltimore
State/Country:	MARYLAND
Postal Code:	21201

## PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11054398

### **CORRESPONDENCE DATA**

Fax Number: 4107061066

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 410-706-2380

Email: gknot001@umaryland.edu

Correspondent Name: Gail Knott

Address Line 1: 620 W. Lexington Street, 4th floor
Address Line 2: Office of Research & Development
Address Line 4: Baltimore, MARYLAND 21201

ATTORNEY DOCKET NUMBER: LW-2010-140

NAME OF SUBMITTER: Gail Knott

**Total Attachments: 3** 

source=LW-2010-140USUMBlassign#page1.tif source=LW-2010-140USUMBlassign#page2.tif source=LW-2010-140USUMBlassign#page3.tif

PATENT REEL: 029288 FRAME: 0084 CH \$40.00 110543

#### PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT is made as of the date of the last signature on the signature page ("Effective Date"), by and between UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE, having a principal place of business at 701 East Pratt Street, Suite 200, Baltimore, MD 21202 ("Assignor") and UNIVERSITY OF MARYLAND, BALTIMORE, by its Office of Commercial Ventures and Intellectual Property, 620 West Lexington Street, 4<sup>th</sup> Floor, Baltimore, Maryland 21201 ("Assignee"). Assignor and Assignee are each institutions of the University System of Maryland ("USM"), a public corporation and an instrumentality of the State of Maryland.

WHEREAS, the assets of Assignor are being transferred to various institutions of the USM; and

WHEREAS, the Institute of Human Virology ("IHV") was transferred to Assignee on July 1, 2007; and

WHEREAS, Assignor is the exclusive owner of all right, title, and interest in and to the patent(s) and patent application(s) identified in **Exhibit A** attached hereto; and

WHEREAS, Assignee desires to acquire all right, title, and interest in and to said patents and patent applications; and

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, **Assignor** hereby assigns to **Assignee** all right, title, and interest to all intellectual property identified in **Exhibit A** attached hereto, and in any and all United States and/or international or foreign patent applications thereon, continuing patent applications thereon (including without limitation substitutions, divisionals, continuations, and continuations-in-part), patents or Letters Patent issued therefrom, and reissues, extensions, renewals, and reexaminations of such applications or patents (collectively, the "**Patents and Patent Applications**").

Such entire right, title, and interest in the Patents and Patent Applications are to be held and enjoyed by Assignee to the same extent as they would have been held and enjoyed by Assignor had this Assignment not been made, to the full end of the term or terms for which any such patent(s) issue. Assignor hereby represents and warrants that Assignor has full right to convey its entire right, title, and interest in and to the Patents and Patent Applications herein assigned, and that Assignor has not executed and will not execute any agreement or other document in conflict therewith.

Assignor agrees to use its best efforts for as long as Assignor exists as a separate entity within the USMto effect such assignment, to execute and deliver separate Assignments, patent applications, and other documents necessary or expedient in connection with, and to cooperate with and to assist Assignee in connection with: further perfecting the assignment of the Patents and Patent Applications to Assignee; Assignee's preparation, filing, prosecution (including without limitation defense in interference proceedings, reexaminations, or litigation), enforcement, and/or maintenance of the Patents and Patent Applications; or for Assignee to protect and commercialize the intellectual property right, title, and interests in and to the Patents and Patent Applications (including without limitation copyright and/or trademarks).

Assignor agrees to use its best efforts for as long as Assignor exists as a separate entity within the USM to pay any direct costs incurred by or on behalf of Assignor prior to the Effective Date of this agreement in association with preparing, filing, prosecuting, enforcing, maintaining, or otherwise protecting the patents and patent applications identified in Exhibit A. Assignee shall not be liable for any

PATENT REEL: 029288 FRAME: 0085 such direct costs incurred by or on behalf of Assignor prior to the Effective Date of this agreement. Assignor shall incur no further costs as of the Effective Date of this agreement.

Assignor hereby requests that the Commissioner of Patents transfer registered ownership of said Patents and Patent Applications, and any reissuance or extension thereof, to the Assignee for the sole use and benefit of the Assignee, its successors, legal representatives and assigns.

ASSIGNOR:	ASSIGNEE:
UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE By: Therach Estert	UNIVERSITY OF MARYLAND BALTIMORE
By: Lywal areas	By: James C. Rh
Name: Edward Eisenstein	Name: Vames L. Hughes
Title: Acting President, UMBI	Vice President, Office of Research and
Date:	Development  Date: 3/3/(0
Witness: GriPhie M. Suefferbad	Witness:
Name: CYNTHIN M. DIEFFEÙBACH	Name: Shari J. Wan

34 of 38

EXHIBIT A INTELLECTUAL PROPERTY ALL PATENT APPLICATIONS REPORT THROUGH 1/19/2010 - IHV

Patent Docket Code Center	e Center	Principal	Inventor(s)	Patent title	Patent firm	Filing Date	Application Status	Patent Application No.	Issue Date	Patent No.
		Investigator								
			Singh, Suddham							
02-002-PCT-EP	<del>Д</del>	Wang	Wang, Dr. Lai-Xi	CARBOHYDRATE-CENTERED AND OTHER SCAFFOLDED MALEIMIDE CLUSTERS: THEIR SYNTHESIS AND APPLICATIONS	MOORE & VAN ALLEN	11/27/2004	Pending	03739275.0-2101		
			Ni, Jiahong			***************************************				
			Singh, Suddham							
02-002-PCT-US	<b>N</b> H	Wang	Wang, Dr. Lai-Xí	CARBOHYDRATE-CENTERED AND OTHER SCAFFOLDED MALEIMIDE CLUSTERS: THEIR SYNTHESIS AND APPLICATIONS	MOORE & VAN ALLEN	12/10/2004	lssned	10/518,108	4/28/2009	7,524,821
			Ni, Jiahong						The state of the s	
			Singh, Suddham					AMBRITAL AMBRITAL AND		
02-002-PRV	ΛH:	Wang	Wang, Dr. Lai-Xí	CARBOHYDRATE-CENTERED AND OTHER SCAFFOLDED MALEIMIDE CLUSTERS: THEIR SYNTHESIS AND APPLICATIONS	MOORE & VAN ALLEN	6/20/2002	Converted to Non-PRV	60/390,776		
			Ni, Jiahong							
			Singh, Suddham							
02-011-PCT	NHI	Wang	Wang, Dr. Lai-Xi	CARBOHYDRATE-BASED SYNTHETIC VACCINES FOR HIV	MOORE & VAN ALLEN	10/14/2003	Entry into Regional Phase	PCT/US03/32496		
02-011-PCT-AU	(H/V	Wang	Wang, Dr. Lai-Xi	CARBOHYDRATE-BASED SYNTHETIC VACCINES FOR HIV	MOORE & VAN ALLEN	10/11/2003	Pending	2003282821	A THE PARTY OF THE	
02-011-PCT-CA	IHV	Wang	Wang, Dr. Lai-Xi	CARBOHYDRATE-BASED SYNTHETIC VACCINES FOR HIV	MOORE & VAN ALLEN	10/11/2003	Pending	2,504,755	A A A A A A A A A A A A A A A A A A A	
02-011-PCT-EP	NH.	Wang	Wang, Dr. Lai-Xi	CARBOHYDRATE-BASED SYNTHETIC VACCINES FOR HIV	MOORE & VAN ALLEN	10/11/2003	Pending	03774819.1-2405		
02-011-PCT-US	NHI.	Wang	Wang, Dr. Lai-Xi	CARBOHYDRATE-BASED SYNTHETIC VACCINES FOR HIV	MOORE & VAN ALLEN	4/11/2003	Pending	10/531,124		
<b>P4</b> 02-011-PRV	NHI	Wang	Wang, Dr. Lai-Xi	CARBOHYDRATE-BASED SYNTHETIC VACCINES FOR HIV	MOORE & VAN ALLEN	10/11/2002	Converted to Non-PRV	60/417,764		
03-042-PRV	NH.	Wang	Wang, Dr. Lai-Xi	ENHANCING ANTI-HIV EFFICIENCY THROUGH MULTIVALENT INHIBITORS TARGETING OLIGOMERIC GP120	MOORE & VAN ALLEN	2/9/2004	Refiled PRV	60/542,916		
			Li, Hengguang							
03-042-PRV-2	<u>₩</u>	Wang	Wang, Dr. Lai-Xi	ENHANCING ANTI-HIV EFFICIENCY THROUGH MULTIVALENT INHIBITORS TARGETING OLIGOMERIC GP120	MOORE & VAN ALLEN	2/26/2004	Converted to Non-PRV	60/548,059		
			Li, Hengguang							
03-042-US	NHI	Wang	Wang, Dr. Lal-Xi	ENHANCING ANTI-HIV EFFICIENCY THROUGH MULTIVALENT INHIBITORS TARGETING OLIGOMERIC GP120	MOORE & VAN ALLEN	2/9/2005	Pending	11/054,398		

PATENT RECORDED: 11/13/2012 REEL: 029288 FRAME: 0087